450 Brookline Ave., Dana 1230, Boston MA 02215 - USA
The mission of Dana-Farber Cancer Institute, founded in 1947, is to provide expert, compassionate care to children and adults with cancer while advancing the understanding, diagnosis, treatment, cure, and prevention of cancer and related diseases.
As an affiliate of Harvard Medical School and a Comprehensive Cancer Center designated by the National Cancer Institute, the Institute also provides training for new generations of physicians and scientists; designs programs that promote public health, particularly among high-risk and underserved populations; and disseminates innovative patient therapies and scientific discoveries to its target community across the United States and throughout the world.
Website: Dana-Farber Cancer Institute
BRIDGET: Secondary BRain metastases prevention after Isolated intracranial progression on Trastuzumab/Pertuzumab or T-DM1 in patients with aDvanced human epidermal Growth factor receptor 2+ brEast cancer with the addition of Tucatinib
Status: Open to Accrual
Read More
Phase 2 Trial of Tremelimumab in Patients With Metastatic Urothelial Cancer Previously Treated With PD-1/PD-L1 Blockade
Status: Closed to Accrual
Read More
A Randomized Phase II Study of Pembrolizumab, an Anti-PD (Programmed Cell Death)-1 Antibody, in Combination With Carboplatin Compared to Carboplatin Alone in Breast Cancer Patients With Chest Wall Disease
Status: Open to Accrual
Read More
Palbociclib in Combination with Fulvestrant or Tamoxifen as Treatment for Hormone Receptor Positive Metastatic Breast Cancer with Prior Chemotherapy for Advanced Disease: A Phase II study with Pharmacodynamics Markers (TBCRC035)
Status: Closed to Accrual
Read More
Facebook
Hoosier Cancer Research Network on Facebook
Linked In
You Tube
Twitter